DXCM FRAUD ALERT: A Securities Fraud Lawsuit has been Filed against DexCom, Inc. – Investors are Notified to Contact BFA Law before October 21 Deadline (Nasdaq:DXCM)

Group 1 - A lawsuit has been filed against DexCom, Inc. and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - DexCom develops glucose monitoring systems for diabetes management and aimed to capitalize on growth potential while scaling customer conversion to the new G7 platform [2] - Following disappointing earnings results for Q2 2024, DexCom reduced its full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion, leading to a significant stock price decline of 38% [2] Group 2 - The stock price of DexCom closed at $107.85 per share on July 25, 2024, and dropped to $66.60 per share by the next trading day [2] - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and has a strong track record, including recovering over $900 million from Tesla's Board of Directors [3][4]